Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

doi:10.1001/jamaoncol.2015.0493

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

JAMA oncology - 1 Jun 2015

Thomas Nancy E, Edmiston Sharon N, Alexander Audrey, Groben Pamela A, Parrish Eloise, Kricker Anne, Armstrong Bruce K, Anton-Culver Hoda, Gruber Stephen B, From Lynn, Busam Klaus J, Hao Honglin, Orlow Irene, Kanetsky Peter A, Luo Li, Reiner Anne S, Paine Susan, Frank Jill S, Bramson Jennifer I, Marrett Lorraine D, Gallagher Richard P, Zanetti Roberto, Rosso Stefano, Dwyer Terence, Cust Anne E, Ollila David W, Begg Colin B, Berwick Marianne, Conway Kathleen

Abstract excerpt

IMPORTANCE: NRAS and BRAF mutations in melanoma inform current treatment paradigms, but their role in survival from primary melanoma has not been established. Identification of patients at high risk of melanoma-related death based on their primary melanoma characteristics before evidence of recurrence could inform recommendations for patient follow-up and eligibility for adjuvant trials. OBJECTIVE: To determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Lymphocytes, Tumor-Infiltrating

Share to Multivariate Analysis

Share to Neoplasm Grading

Share to New South Wales

Share to Proportional Hazards Models

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 26146664
DOI: 10.1001/jamaoncol.2015.0493
PMCID: PMC4486299

Genes

NRAS
BRAF
GEM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.PMID 26146664Read ↗

Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.Semantic proximity Read ↗

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.Semantic proximity Read ↗

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.Semantic proximity Read ↗

Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanomaSemantic proximity Read ↗

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.Semantic proximity Read ↗

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.Semantic proximity Read ↗

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single centerSemantic proximity Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.Semantic proximity Read ↗

From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years.Semantic proximity Read ↗

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Semantic proximity Read ↗

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.